UBS Group
AIDX

UBS Group’s 20/20 Biolabs Inc AIDX Stock Holding History

UBS Group’s Portfolio AIDX Stock Details AIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.6K Buy
+8,314
New +$35.1K ﹤0.01% 8109

Other funds holding AIDX

CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

UBS Group's AIDX Position: Q1 2026 in Review

UBS Group opened a new position in 20/20 Biolabs Inc (AIDX) in Q1 2026: 8,314 shares worth $15.6K. The stake represents ﹤0.01% of the portfolio and ranks #8109 among its holdings.

7 funds tracked by Wall St. Rank hold AIDX as of Q1 2026.

  • UBS Group held 8,314 shares of 20/20 Biolabs Inc worth $15.6K as of Q1 2026.
  • 20/20 Biolabs Inc was a new UBS Group position in Q1 2026.
  • 20/20 Biolabs Inc made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8109 holding.
  • 7 funds tracked by Wall St. Rank held 20/20 Biolabs Inc as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.